Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Follow-up Phase IIa Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 50 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis

Next Previous
X
Search
Trial Profile

A Follow-up Phase IIa Study to Evaluate the Long-term Safety and Efficacy Profile of ABX464 Given at 50 mg Once Daily in Subjects With Moderate to Severe Active Ulcerative Colitis

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 05 Mar 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obefazimod (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions
  • Sponsors Abivax

    • Most Recent Events

    • 22 Jan 2023 This trial has been completed in Poland according to European Clinical Trials Database record.
    • 20 Aug 2022 The trial has been completed in Begium and Hungary, according to European Clinical Trials Database record
    • 01 Mar 2021 Results assessing and efficacy and safety from TRACK study at 8 weeks and from long-term extension study at months 12 and 24 published in the Gastroenterology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top